Genmab A/S
GMAB33.420USD
-0.300-0.89%
收盘 12/26, 16:00（美东）报价延迟15分钟
20.58B总市值
14.14市盈率 TTM
关于 Genmab A/S 公司
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Genmab A/S简介
公司代码GMAB
公司名称Genmab A/S
上市日期Oct 01, 2000
CEOVan De Winkel (Jan G.J)
员工数量2682
证券类型Depository Receipt
年结日Oct 01
公司地址Carl Jacobsens Vej 30
城市VALBY
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Denmark
邮编2500
电话4570202728
网址https://www.genmab.com/
公司代码GMAB
上市日期Oct 01, 2000
CEOVan De Winkel (Jan G.J)
Genmab A/S公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Ms. Mijke Zachariasse, Ph.D.
Ms. Mijke Zachariasse, Ph.D.
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Ms. Elizabeth A. O'farrell
Ms. Elizabeth A. O'farrell
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Royalties
789.00M
85.30%
Net product sales
101.00M
10.92%
Collaboration revenue
21.00M
2.27%
Reimbursement income
13.00M
1.41%
Milestone payments
1.00M
0.11%
由于公司未披露，未能获取相关数据
业务
地区
业务USD
名称
营收
占比
Royalties
789.00M
85.30%
Net product sales
101.00M
10.92%
Collaboration revenue
21.00M
2.27%
Reimbursement income
13.00M
1.41%
Milestone payments
1.00M
0.11%
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Orbis Investment Management Ltd.
1.80%
AllianceBernstein L.P.
1.78%
Paradigm BioCapital Advisors LP
0.62%
Arrowstreet Capital, Limited Partnership
0.59%
Harding Loevner LP
0.57%
其他
94.64%
持股股东
持股股东
占比
Orbis Investment Management Ltd.
1.80%
AllianceBernstein L.P.
1.78%
Paradigm BioCapital Advisors LP
0.62%
Arrowstreet Capital, Limited Partnership
0.59%
Harding Loevner LP
0.57%
其他
94.64%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
4.59%
Investment Advisor
3.46%
Hedge Fund
1.96%
Research Firm
0.19%
Pension Fund
0.03%
Bank and Trust
0.02%
Family Office
0.01%
Venture Capital
0.01%
其他
89.71%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
515
64.81M
10.54%
-15.68M
2025Q2
501
65.30M
10.31%
-6.21M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
2023Q3
479
48.54M
7.43%
+204.98K
2023Q2
467
42.76M
6.55%
-5.77M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Orbis Investment Management Ltd.
7.92M
1.29%
+2.21M
+38.69%
Jun 30, 2025
AllianceBernstein L.P.
10.66M
1.73%
-4.06M
-27.59%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
3.45M
0.56%
+2.08M
+152.25%
Jun 30, 2025
Harding Loevner LP
2.92M
0.48%
+42.61K
+1.48%
Jun 30, 2025
Two Sigma Investments, LP
3.44M
0.56%
-433.92K
-11.20%
Jun 30, 2025
Renaissance Technologies LLC
2.77M
0.45%
+504.40K
+22.30%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.50M
0.41%
-443.29K
-15.04%
Jun 30, 2025
First Trust Advisors L.P.
1.77M
0.29%
+60.50K
+3.54%
Jun 30, 2025
Parametric Portfolio Associates LLC
1.19M
0.19%
-6.41K
-0.54%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Tema Oncology ETF
4.2%
First Trust NYSE Arca Biotechnology Index Fund
3.02%
WisdomTree BioRevolution Fund
1.31%
iShares Biotechnology ETF
1.15%
AB Disruptors ETF
0.69%
JPMorgan Healthcare Leaders ETF
0.28%
First Trust NASDAQ BuyWrite Income ETF
0.26%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
ActivePassive International Equity ETF
0.12%
查看更多
Tema Oncology ETF
占比4.2%
First Trust NYSE Arca Biotechnology Index Fund
占比3.02%
WisdomTree BioRevolution Fund
占比1.31%
iShares Biotechnology ETF
占比1.15%
AB Disruptors ETF
占比0.69%
JPMorgan Healthcare Leaders ETF
占比0.28%
First Trust NASDAQ BuyWrite Income ETF
占比0.26%
ProShares Ultra Nasdaq Biotechnology
占比0.12%
Invesco Nasdaq Biotechnology ETF
占比0.12%
ActivePassive International Equity ETF
占比0.12%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Genmab A/S的前五大股东是谁？
Genmab A/S 的前五大股东如下：
Orbis Investment Management Ltd.持有股份：7.92M，占总股份比例：1.29%。
AllianceBernstein L.P.持有股份：10.66M，占总股份比例：1.73%。
Arrowstreet Capital, Limited Partnership持有股份：3.45M，占总股份比例：0.56%。
Harding Loevner LP持有股份：2.92M，占总股份比例：0.48%。
Two Sigma Investments, LP持有股份：3.44M，占总股份比例：0.56%。
Orbis Investment Management Ltd.持有股份：7.92M，占总股份比例：1.29%。
AllianceBernstein L.P.持有股份：10.66M，占总股份比例：1.73%。
Arrowstreet Capital, Limited Partnership持有股份：3.45M，占总股份比例：0.56%。
Harding Loevner LP持有股份：2.92M，占总股份比例：0.48%。
Two Sigma Investments, LP持有股份：3.44M，占总股份比例：0.56%。
Genmab A/S的前三大股东类型是什么？
Genmab A/S 的前三大股东类型分别是：
Orbis Investment Management Ltd.
AllianceBernstein L.P.
Paradigm BioCapital Advisors LP
Orbis Investment Management Ltd.
AllianceBernstein L.P.
Paradigm BioCapital Advisors LP
有多少机构持有Genmab A/S(GMAB)的股份？
截至2025Q3，共有515家机构持有Genmab A/S的股份，合计持有的股份价值约为64.81M，占公司总股份的10.54%。与2025Q2相比，机构持股有所增加，增幅为0.23%。
哪个业务部门对Genmab A/S的收入贡献最大？
在FY2025Q2，Royalties业务部门对Genmab A/S的收入贡献最大，创收789.00M，占总收入的85.30%。
